Dan Peer is a Professor and Director of the Laboratory of Precision Nanomedicine and Vice President for Research at Tel Aviv University. Dan was trained at Tel Aviv University with fellowships at the University of Cambridge, UK, at MIT, and as a postdoctoral Fellow at Harvard Medical School. He returned to Tel Aviv University to establish the laboratory of Precision Nanomedicine in 2008. Dan pioneered the field of Active Cellular Targeting (ACT) to deliver RNA payloads in a cell specific manner. He developed one of the largest lipid libraries with more than 100,000 different lipids. His lab was the first to show systemic, cell specific delivery of siRNAs to immune cells. The first to show systemic, cell specific mRNA delivery in an animal model that express a therapeutic protein; and the first to show highly efficient therapeutic genome editing in cancer - also in a cell type specific manner. He also developed the first bacterial mRNA vaccine; He is the recipient of more than 40 awards and honors (among them the 2026 Rappaprt Prize for Excellence in Biomedical Research, the Landau Price in Nanotechnology and the 2026 CRS Founders Award). He holds 161 pending and granted patents, 63% of them are licensed to companies and more than 10 strategies currently in clinical trias. He is the founder of 4 startup companies (one was acquired in 2021). Dan also serves as an editor and on the editorial board of more than 20 journals. Dan was elected to the US National Academy of Engineering in 2023. He is an elected Fellow of the US National Academy of Inventors (2024) and a Fellow of the CRS (2025).